MENU
+Compare
FMED
ETF ticker: NASDAQ
AS OF
Dec 18, 12:28 PM (EDT)
Price
$25.58
Change
-$0.01 (-0.04%)
Net Assets
54.42M

FMED stock forecast, quote, news & analysis

Category: @Health
FMED
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
A.I.Advisor
a Summary for FMED with price predictions
Dec 17, 2024

FMED sees MACD Histogram just turned negative

FMED saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on December 13, 2024. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 14 instances where the indicator turned negative. In of the 14 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on December 12, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on FMED as a result. In of 27 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

FMED moved below its 50-day moving average on December 12, 2024 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where FMED declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where FMED's RSI Indicator exited the oversold zone, of 9 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The 10-day moving average for FMED crossed bullishly above the 50-day moving average on December 04, 2024. This indicates that the trend has shifted higher and could be considered a buy signal. In of 2 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where FMED advanced for three days, in of 76 cases, the price rose further within the following month. The odds of a continued upward trend are .

FMED may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Unitedhealth Group (NYSE:UNH), Merck & Co (NYSE:MRK), Intuitive Surgical (NASDAQ:ISRG), Boston Scientific Corp (NYSE:BSX), Regeneron Pharmaceuticals (NASDAQ:REGN), Edwards Lifesciences Corp (NYSE:EW), Humana (NYSE:HUM), Centene Corp (NYSE:CNC), Align Technology (NASDAQ:ALGN).

Industry description

The investment seeks long-term growth of capital. The fund normally invests at least 80% of assets in securities of disruptive medicine companies. Fidelity's disruptive strategies seek to identify innovative developments that could signal new directions for delivering products and services to customers. Generally, these companies have or are developing new or unconventional ways of doing business that could disrupt and displace incumbents over time. The fund is non-diversified.

Market Cap

The average market capitalization across the Fidelity Disruptive Medicine ETF ETF is 51.72B. The market cap for tickers in the group ranges from 94.41M to 739.66B. LLY holds the highest valuation in this group at 739.66B. The lowest valued company is ALXO at 94.41M.

High and low price notable news

The average weekly price growth across all stocks in the Fidelity Disruptive Medicine ETF ETF was 31%. For the same ETF, the average monthly price growth was 63%, and the average quarterly price growth was 96%. ALXO experienced the highest price growth at 13%, while KROS experienced the biggest fall at -73%.

Volume

The average weekly volume growth across all stocks in the Fidelity Disruptive Medicine ETF ETF was 26%. For the same stocks of the ETF, the average monthly volume growth was -24% and the average quarterly volume growth was 16%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 63
P/E Growth Rating: 70
Price Growth Rating: 52
SMR Rating: 78
Profit Risk Rating: 70
Seasonality Score: -3 (-100 ... +100)
View a ticker or compare two or three
FMED
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
82 Devonshire StreetBoston
Phone
N/A
Web
www.institutional.fidelity.com